“This is a remarkable step forward in how we approach patients who may not be ideal candidates for surgery because of severely leaky tricuspid valves,” said Dr. Bethea. “They are often complicated by ...

2006;9(10):691-696. The following sections present information about the most commonly implanted (contemporary) mechanical and bioprosthetic heart valves. The intent is to familiarize the reader ...

As the heart muscle contracts, it propels the blood out into the vascular system. The heart’s chambers and valves are arranged to direct the flow of the blood as the heart beats. The heart has two ...

Double and triple VHD were thus defined as the presence of moderate or greater lesions on any 2 or all 3 native heart valves of interest, respectively. Any VHD considered patients with a stenotic or ...

Acclaimed heart surgeon Professor Sir Magdi Yacoub is spearheading a revolutionary new project in the UK that will soon allow patients to be given new heart valves that naturally grow inside their ...

Renowned heart surgeon Professor Sir Magdi Yacoub has unveiled a groundbreaking advancement in cardiac care: a “living valve” that grows naturally within a patient’s body. Sir Magdi Yacoub, reflecting ...

King of Hearts Sir Magdi Yacoub has unveiled a groundbreaking advancement in heart valve transplantation, valves that grow naturally in the body, integrating tissue engineering and stem cell ...

This pioneering innovation envisions the development of biological heart valves that can grow and be accommodated naturally within the human body. This opens the door to a new era in heart disease ...

Background Valve-related haemolysis is a known complication following ... Reintervention procedure was determined by the heart team discussion, taking into account the degree of aortic regurgitation, ...

The good news is that science is finding ways to help. Breakthroughs like stem cell therapy and bioengineered heart valves are creating new possibilities for treatment and recovery. These ...

In the RESHAPE-HF2 trial, 505 patients with systolic HF (left ventricular ejection fraction 20-50% and New York Heart Association [NYHA] class II ... the patients in the RESHAPE-HF2 trial had less ...